TG Therapeutics entered into the First Amendment to its Financing Agreement on March 18, 2026, establishing a $750 million 2026 Term Loan facility fully borrowed on the Closing Date to repay prior Initial Term Loans, and an uncommitted $250 million additional facility. The term loan matures on March 18, 2031, is secured by substantially all assets, and features interest based on SOFR or base rate plus applicable margin.
Key takeaways
Entered First Amendment on March 18, 2026, amending August 2, 2024 Financing Agreement
$750 million 2026 Term Loan borrowed in full on Closing Date to repay Initial Term Loans
Uncommitted additional facility up to $250 million
Maturity date March 18, 2031
Interest at applicable margin (starting 4.75% SOFR/3.75% base) plus Term SOFR (floor 1%) or base rate
Quarterly amortization of $37.5 million starting March 31, 2030, deferrable if leverage threshold met
Secured by lien on substantially all assets of Borrower and guarantors